Neisserial antigenic peptides
CA 2389321 A1 · Owner: Novartis Vaccines And Diagnostics S.R.L. · Inventors: Scarlato, Vincenzo; Ratti, Guilio; Grandi, Guido
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention provides, among other things proteins, polypeptides, and , fragments thereof derived from the bacteria Neisseria meningitidis B. Also provided are nucleic acids encoding for such proteins polypeptides, and/or , fragments, as well as nucleic acids complementary thereto e.g. antisense nucleic acids). Additionally, this invention provides antibodies which bind to the proteins, polypeptides, and/or fragments. This invention further provides expression vectors useful for making the proteins polypeptides, and/or , fragments, as well as host cells transformed with such vectors. This invention also provides compositions of the proteins polypeptides, fragments, and/or , nucleic …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 30, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 30, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 30, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.